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WORKSHOP REPORT 
WORKSHOP ON TROPHIC FACTORS IN THE PERIPHERAL NERVOUS 
SYSTEM. CAPRI, OCTOBER 1991 
Neurotrophic factors have been shown to have 
important functions in the maintenance of spe-
cific properties of peripheral and central neurons. 
At a recent meeting [Miniworkshop on Trophic 
Factors in the Peripheral Nervous System, Capri, 
Italy, 8~9 October 1991; organized by the European 
Alliance of Muscular Dystrophy Associations 
(EAMDA), sponsored by the Italian NMD-
association (UILDM)] work performed in this 
field by several European research groups was 
presented and discussed in light of its possible 
relevance to neurogenic neuromuscular dis-
orders. The abstracts summarizing the present-
ations given at this mini workshop will be 
published elsewhere [1]. 
Success in the co-ordination of European 
research efforts in the field of muscular dystrophy 
has encouraged EAMDA to begin to focus on 
basic research on neurogenic neuromuscular 
disorders. Several important steps have been 
made in this field during the last few years: 
the molecular cloning of several new neuro-
trophic factors [brain-derived neurotrophic fac-
tor (BDNF), neurotrophin-3 and -4 (NT-3 and 
NT-4), ciliary neurotrophic factor (CNTF)] [2~ 
7], the identification of a gene family of receptor 
molecules for some of these factors (reviewed in 
Ref. [8]), and progress in the understanding of 
the effects of polypeptide growth factors on 
muscle cell differentiation, neuronal sprouting 
[insulin-like growth factor I and 11 (IGF-I and 
IGF-II)] [9], and in vitro motoneuron survival 
(CNTF, the IGFs and basic FGF [IO~ 12]). The 
intention of the organizers was to bring together 
European scientists working in this field in order 
to discuss the clinical implications of these 
new findings. In particular, the present state of 
knowledge and the insufficient transfer of these 
basic research findings to clinical progress were 
discussed. Suggestions for support of such re-
search efforts were made by the organizers, 
including the co-ordination of efforts to enable 
investigations with autopsy and, where possible, 
biopsy material and the establishment of a 
decentralized nerve tissue bank. Such a tissue 
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bank would be a prerequisite for investigations 
concerning the question whether pathophysio-
logical findings from animal models (regulation 
of expression of neurotrophic factors and their 
receptors, effects of the application of poly-
peptide factors on neuronal and muscle differ-
entiation and regeneration under experimental 
conditions) can be correlated with defined path-
ological changes in humans. The presentations 
focused on several topics: 
(1) the reaction of bulbar and spinal moto-
neurons after injury (G. W. Kreutzberg, Mar-
tinsried, F.R.G.); 
(2) the molecular identification of new mem-
bers of the nerve growth factor gene family, their 
expression in different regions of the central 
nervous system both during development and 
under pathophysiological conditions in the adult 
(H. Persson, Stockholm, Sweden); 
(3) the identification of neurotrophic factors 
for embryonic spinal motoneurons (c. Mettling, 
Montpellier, France) and the characterization of 
the in vitro and in vivo survival effects of CNTF 
on spinal and facial motoneurons in comparison 
with other neurotrophic molecules and cytokines 
(M. Sendtner, Martinsried, F.R.G.); 
(4) the identification of the trk oncogene as the 
signal transducing unit acting together with P75 
as the high-affinity receptor for NGF (R. Martin-
Zanca, Salamanca, Spain); 
(5) the action, expression and regulation of 
IGF-I and IGF-II in the neuromuscular system 
(P. Caroni, Basel, Switzerland); 
(6) the actions of synthetic peptide homo-
logues of ACTH and aMSH on axonal regen-
eration and protection of neurons from toxic 
neuropathy caused by cisplatin (F. J. Jennekens, 
Utrecht, The Netherlands); and 
(7) methods of culturing Schwann cells from 
adult rodents and humans were presented in 
order to analyse specific properties of these cells, 
to identify possible species differences and to 
obtain sufficient quantities of cultured Schwann 
cells for transplantation purposes (E. Scarpini, 
Milano, Italy). 
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The presentations on these topics were com-
plemented by a report from M. C. Lagrange on 
research efforts in these fields performed by 
groups in France supported by the French 
Muscular Dystrophy Association (AFM). AFM 
supports a broad spectrum of research activities 
in the field of motoneuron diseases, which in-
cludes the development of new monoclonal 
antibodies for spinal motoneurons, the estab-
lishment of motoneuron cell lines and the graft-
ing of motoneurons. Furthermore, Mrs Lagrange 
reported on research efforts of French groups on 
the creation of new mouse models for neuro-
muscular disease using genetic manipulation 
techniques, and the molecular analysis of the 
genetic defect of the "wobbler mouse" , a well-
known mouse mutant, which suffers from a yet 
unknown genetic defect leading to the degen-
eration of bulbar and spinal motoneurons [13-
15]. 
RETROGRADE REACTIONS OF MOTONEURONS 
AFTER INJURY 
G. W. Kreutzberg gave a summary of the 
cellular and molecular reactions observed in 
motoneurons after injury and during regen-
eration. The ultrastructural equivalent of the 
morphological changes known as chromatolysis 
and retrograde or axon reaction is an enormous 
increase in the number of ribosomes, and a 
redistribution of the granular endoplasmic reti-
culum, which is characterized by a disintegration 
of the cisternal arrangement. During this phase 
motoneurons show an overall increase in protein 
synthesis, glucose uptake, hexose monophos-
phate metabolism, in addition to enhanced iron 
metabolism and upregulation of transferrin re-
ceptor expression. Whereas enzyme activities 
such as ornithine decarboxylase are dramatically 
upregulated, others involved in neurotransmitter 
metabolism, such as acetylcholinesterase, ap-
parently are downregulated. The changes ob-
served in the motoneurons themselves are paral-
leled by accompanying reactions of the glial 
environment. Glial reactions include the local 
proliferation of microglial cells, which are in-
volved in the displacement of presynaptic ter-
minals from dendrites and cell somata oflesioned 
motoneurons (synaptic stripping), and reactions 
of surrounding astrocytes (induction of GFAP, 
formation of lamellar stacks around regenerat-
ing neurons). These morphological changes seem 
to be the basis for the chronic reduction of 
inhibitory inputs to the cell bodies detectable in 
lesioned motoneurons, and might therefore ex-
plain the well-known phenomenon that regen-
erating or chromatolytic motoneurons become 
hyperexcitable. 
Present research focuses on the signals in-
volved in these complex cellular reactions. One 
signalling molecule candidate is the calcitonin 
gene related peptide (CGRP). CGRP is known to 
affect distinct properties of muscle fibres such as 
cAMP synthesis [16] and acetylcholine receptor 
expression [17]. The expression of CGRP is 
increased rapidly in axotomized motoneurons 
[18], and several groups are presently invest-
igating a possible role for this molecule in 
neuron- glia signalling. 
THE NERVE-GROWTH-FACTOR GENE FAMILY: 
UNRESOLVED FUNCTIONS FOR MOTONEURONS 
Nerve-growth-factor is a small basic, secretory 
molecule which is known to support the survival 
of several neuronal populations such as neural 
crest-derived sympathetic and sensory neurons 
and cholinergic neurons within the central ner-
vous system. However, NGF does not support 
the survival of spinal and bulbar motoneurons, 
although NGF has been shown to bind to these 
neurons via its low-affinity receptor (P75) [19, 20] 
and be retrogradely transported in motoneurons 
[21] . The P75 molecule is expressed at high levels 
in rat spinal cord motoneurons at the time of 
naturally occurring cell death during embryonic 
development. After that time period the ex-
pression of this molecule is downregulated, but 
can be induced again in motoneurons after 
axonal lesion. Recently other NGF related 
molecules such as BDNF, NT-3 and NT-4, have 
been identified and cloned [2- 5]. In their bio-
logically active form, these molecules share a 
significant portion of amino acid identity (about 
50%). It has been shown that BDNF also binds 
to the low-affinity NGF receptor P75 molecule 
with the same affinity as NGF itself [22], namely 
10- 9 M, and it seems very likely that NT-3 and 
NT-4 share this property. Present investigations 
are focusing on the question whether there might 
be a member of the NGF gene family which 
could serve as a functional, survival-promoting 
molecule for spinal motoneurons. At least in 
vitro, NT-3 seems to be unable to support the 
survival of embryonic chick spinal motoneurons 
[10], but not much is known yet about the 
physiological role of this molecule in vivo. In the 
case of NT-4 [5], nothing is known so far about 
Workshop Report 13 
the distribution of this factor in vivo, and which 
neurons of the central nervous system respond 
to it. 
The highest levels of NGF, BDNF and NT-3 
mRNA within the brain are found in the hippo-
campus, and in situ hybridization data indicate 
that the expression patterns for these molecules 
are regionally different. NGF and BDNF mRNA 
expression in the adult rat brain is regulated by 
neuronal activity [23, 24], and Hakan Persson 
reported on results obtained by his group show-
ing the upregulation of these factors following 
epileptic seizures and the regulation during 
kindling associated neural plasticity [25]. 
Recently, it has been reported by the same 
group that NT-3 mRNA is expressed by spinal 
motoneurons during embryonic development 
[26]. Highest levels were found from embryonic 
days 13- 16. After that period NT-3 expression in 
the adult spinal cord decreased up to postnatal 
day I and could not be detected in the adult rat 
spinal cord. The physiological role of these data 
is not yet clear. The authors hypothesize that 
NT-3 synthesized by spinal motoneurons could 
function in vivo as target- derived trophic support 
for proprioceptive sensory neurons of the dorsal 
root ganglion. Indeed, these neurons have been 
shown to respond to NT-3, at least in vitro [3]. 
THE MOLECULAR IDENTIFICATION OF 
MOTONEURON SURVIVAL FACTORS 
Improved isolation and culture techniques for 
embryonic chick spinal motoneurons have led to 
the identification and characterization of sur-
vival activities and molecules for these neurons. 
Mettling reported on a culture technique based 
on the enrichment of embryonic day 4 chick 
spinal motoneurons by panning with the mono-
clonal antibody SCI [11]. In these cultures 
skeletal muscle extract was able to enhance 
neuronal survival, whereas bFGF was active 
only in the presence of 10% horse serum, and not 
under serum-free culture conditions. It was 
therefore concluded that serum might contain a 
co-factor required for bFGF action. Replace-
ment of serum by heparin, NGF, or CNTF did 
not enhance neuronal survival in these cultures, 
indicating that none of these factors are com-
ponents of the serum activity. However, the 
action ofbFGF was significantly enhanced in the 
presence of transforming-growth-factor-beta 
(TGF [3), which showed similar effects to serum in 
the cultures for time periods of at least 3 days. 
Mettling also reported on a strategy for the 
expression cloning of motoneuron survival 
molecules based on Xenopus oocyte injection. 
The authors used mRNA from denervated mus-
cle and could show that a mRNA molecule 
contained in this preparation might encode for a 
secreted protein capable of supporting the sur-
vival and promoting neurite outgrowth of spinal 
motoneurons. They are working presently on the 
molecular identification and characterization of 
this activity. 
Another technique for the enrichment of em-
bryonic day 6 chick spinal motoneurons has been 
reported [10]. The physiological period of nat-
urally occurring motoneuron cell death in the 
chick begins at the same time and it is known that 
the cells are dependent on survival factors at this 
stage. After retrograde labelling in ovo with a 
fluorescent dye the ventral parts of the spinal 
cord were prepared , dissociated with the moto-
neurons enriched by density gradient centri-
fugation. The cultures consisted of at least 80% 
motoneurons, and the survival of nearly all of 
these cells could be supported by muscle extract, 
which was chosen as a positive control. Under 
these conditions, CNTF, at a concentration of 
1.5 ng ml - I , supported maxim ally 64% of the 
initially plated spinal motoneurons after 3 days 
in culture. Similar results were obtained in single 
cell cultures, demonstrating that CNTF acts 
directly on motoneurons [27]. Whereas NGF, 
NT-3 and BDNF did not support the survival of 
motoneurons in these cultures, bFGF and aFGF 
showed significant effects, which were additive to 
that of CNTF resulting in a survival of actually 
100% of cultured motoneurons in the presence of 
CNTF and bFGF. Of a variety of other mole-
cules (includingPDGF, EGF, TGFa, TGF[3, IL-
I, IL-3, IL-6) tested in the same culture system, 
only IGF-I and IGF-II showed a small survival 
effect at high concentrations (15% of the ori-
ginally plated motoneurons in comparison with 
5% survival without the addition of specific 
survival factors) . 
The cloning of CNTF [6, 7] has revealed that 
this factor does not belong to the NGF gene 
family and differs significantly from these mole-
cules. The absence of a hydrophobic leader 
sequence, typical for secretory proteins, and its 
non-release from transfected HeLa cells indicate 
that CNTF is a cytosolic molecule which might 
be released only after cell death or by as yet 
unidentified, specific release mechanisms. High 
levels ofCNTF mRNA and protein are found in 
Schwann cells of peripheral nerves and in astro-
cytes within restricted regions of the CNS, such 
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as the optic nerve and olfactory bulb [28]. 
However, in typical target tissues of responsive 
neurons, such as adult rat skeletal muscle or skin, 
CNTF mRNA cannot be detected. In the rat, 
CNTF expression cannot be detected by North-
ern blot or PCR analysis, either during em-
bryonic development or shortly after birth, but 
during the following postnatal weeks a more 
than 30-fold increase of CNTF-mRNA and 
protein can be observed in the sciatic nerve and 
distinct areas within the CNS. Since the post-
natal period of low CNTF levels in peripheral 
nerves coincides with the time of high vul-
nerability of motoneurons after lesion, insuf-
ficient availability of CNTF may be responsible 
for the high rates of cell death after lesion of 
young neurons. This hypothesis is supported by 
the finding that the extensive degeneration of 
motoneurons in the newborn rat facial nucleus 
after transection of the facial nerve can be 
prevented by local CNTF administration [29] . 
CNTF might therefore play a physiological role 
in the adult as a lesion factor for injured spinal 
motoneurons. 
trk PROTO-ONCOGENES: FUNCTION AS 
RECEPTORS FOR NEUROTROPHIC FACTORS 
The cloning of the low-affinity NGF receptor 
(P75) [30, 31] revealed that the molecule is a 
75- 80 kDa intrinsic membrane molecule with a 
relatively short cytoplasmic domain without 
typical structural domains known to be involved 
in signal transduction . Evidence for a different 
protein involved in the high-affinity binding of 
NGF has already been obtained by cross-linking 
experiments which reveal a second, 160 kDa 
complex (consisting of NGF and a presumptive 
140 kDa protein) on NGF responsive cells [32]. 
Martin-Zanca et al. [33] have shown that the 
human trk proto-oncogene encodes a 140 kDa 
transmembrane tyrosine kinase molecule. Sub-
sequent in situ hybridization experiments by the 
same authors have shown that this molecule in 
embryonic mice is predominantly expressed in 
neural crest-derived neuronal cells. Based on 
these studies NGF has been identified as a ligand 
able to bind to trk and to induce its tyrosine 
autophosphorylation [34-36] suggesting that this 
molecular event might be the first step in a 
cascade resulting in the cellular responses evoked 
by NGF in responsive cells. In addition, it has 
been shown that there are other molecules of a 
gene family which share significant sequence 
homologies with trk (for recent reviews see Refs 
[8, 37]). Binding analysis has revealed that trkB 
might serve as a receptor for BDNF and/or NT-3 
[38]. It is not yet known whether spinal moto-
neurons express transmembrane molecules of the 
trk gene family. The identification of such a 
molecule and appropriate ligand would be a 
promising step towards the characterization of 
the mechanisms involved in the regulation of 
motoneuron survival during development. 
THE ROLE OF INSULIN-LIKE GROWTH FACTORS IN 
THE NEUROMUSCULAR SYSTEM 
IGF-I and IGF-II are synthesized by a variety 
of tissues, including the liver, pituitary, and 
nervous system, and are present in relatively high 
concentrations in serum and cerebral fluid [39] . 
During the last few years evidence has increased 
suggesting that these factors could play a phy-
siological role in the neuromuscular system: they 
have been shown to promote neurite outgrowth 
from sympathetic and sensory neurons [39] and 
IGF-I is retrogradely transported by fast axonal 
transport in the sciatic nerve of the adult rat [40]. 
Pi co Caroni reported work performed by his 
group on the analysis of IGF-I and IGF-II as 
candidates for the diffusible sprouting activity for 
motoneurons in adult inactivated muscle. They 
have found that embryonic chick motoneurons 
in culture can survive and grow neurites in the 
presence of IGF-I and JGF-U, and that they 
express high-affinity binding sites for these mole-
cules on their cellular processes [9]. They also 
have found that injection of IGF-II on the 
surface of the gluteus muscle of the adult rat 
induces nodal sprouting of innervating nerve 
fibres and terminal sprouting at the endplates. 
During development both IGF-I and IGF-II 
mRNA expression in muscle are sharply de-
creased at the onset of the developmental period 
of synapse elimination, and the mRNAs for both 
factors are re-expressed in skeletal muscle after 
denervation. GAP-43 and tubulin a 1 expression 
in motoneurons, which are also both decreased 
during synapse elimination, can be maintained at 
significant levels by the local addition of exo-
genous IGF-I during the period of synapse 
elimination. The increase of IGF-I mRNA after 
muscle denervation in adult animals appears to 
occur more rapidly than that ofIGF-II, and both 
the muscle fibres and interstitial cells might be the 
source of these factors 1 week after muscular 
denervation. In addition to the increased IGF 
expression in muscle, IGF-I receptor mRNA 
expression is induced in the corresponding spinal 
.. 
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motoneurons. These results could indicate that 
elevated levels of IGFs in denervated muscle 
trigger co-ordinate regenerative reactions which 
lead to nerve sprouting under these pathophys-
iological conditions. 
CLINICAL EXPERIENCES WITH ACTH ANALOGUES 
IN THE TREATMENT OF NEUROMUSCULAR 
DISEASE 
In contrast to the neurotrophic factors and 
cytokines described earlier, pep tides derived 
from the amino acid sequence of ACTH have 
already been used for clinical applications in 
degenerative diseases such as Alzheimer's disease 
and in neurotoxic lesions. Such studies are based 
on earlier work on the effects of melanocortins on 
axonal regeneration . In particular, a synthetic 
analogue of amino acids 4-9 of the ACTH 
peptide sequence has been shown to increase 
sprouting after a crush lesion of the sciatic nerve 
in the adult rat [41]. In the unlesioned neuro-
muscular system, a synthetic analogue of this 
peptide (ORG 2766) can induce sprouting of 
intramuscular nerves [42]. However, it is not 
yet clear how this peptide exerts its effects 
at a cellular basis. In particular, it is not 
known whether the effects are caused directly 
after binding to specific receptors on moto-
neurons, or indirectly by inducing the synthe-
sis of other factors such as the IGFs known to 
affect the regeneration and/or sprouting of 
motoneurons. 
The same synthetic analogue of ACTH 4-9 has 
been used in animal studies with rats and also in 
patients suffering from cisplatin-induced neuro-
pathy [43, 44]. Treatment of rats with cisplatin 
lowers the increase of conduction velocity of 
sensory nerve fibres detectable during normal 
postnatal development. In the presence of the 
ACTH 4- 9 analogue ORG 2766 this neurotoxic 
effect of cisplatin can be completely abolished. 
Promising effects were also seen in patients 
suffering from cisplatin neuropathy during 
chemotherapy of ovarian carcinoma. Cisplatin-
treated patients showed a marked increase in the 
vibration sense threshold, which the simultan-
eous application ofORG 2766 could antagonize. 
The effect ofORG 2766 was dose dependent [44]. 
These results might encourage further studies on 
the mechanisms of action for these peptides, 
which could give deeper insights into the physio-
logical role of melanocortins in the function of 
spinal motoneurons. 
HUMAN SCHWANN CELLS IN CULTURE: 
PROPERTIES AND PROSPECT FOR CLINICAL 
APPLICATION 
Schwann cells play an important role in the 
maintenance of motoneuron function in vivo . 
Indeed, the integrity of the myelin sheath is 
necessary for neuronal signal transduction. 
Under pathophysiological conditions, such as 
nerve lesion, Schwann cells present cell surface 
molecules and extracellular matrix components 
as well as being the source of neurotrophic 
factors such as NGF, BDNF and CNTF, mole-
cules which have been shown to exert distinct 
effects on the regeneration of lesioned nerve 
fibres . In order to study both the molecular 
events leading to differentiation/myelination and 
to obtain cells for transplantation purposes, 
several techniques have been developed for the 
isolation and culture of Schwann cells. In most 
cases tissues from newborn rats, nerves or spinal 
ganglia are used. Techniques for the purification 
of Schwann cells from adult rat sciatic nerves 
have also been described which allow the specific 
properties of these cells after postnatal differ-
entiation to be studied [45]. This method includes 
steps to overcome the technical problems caused 
by the abundance of connective tissue and myelin 
in nerves at that stage, and more than 80% of the 
cells obtained by this method were estimated to 
be Schwann cells by S-IOO staining during the 
first 3 days in culture. Scarpini and his group 
have used a similar method to prepare human 
Schwann cells from normal adult and foetal 
nerves. These Schwann cells showed immuno-
logical properties similar to the cells prepared 
from rat sciatic nerves, such as positive staining 
for S-IOO, HNK-l, PO, Gal-C and P75 . In the 
presence of platelet-derived growth factor (PDGF) 
and forskolin a significant proliferative response 
could be observed in the Schwann cell cultures, a 
prerequisite for obtaining large numbers of these 
cells for transplantation purposes suitable for the 
treatment of damage to the peripheral nervous 
system. 
CONCLUSIONS AND FUTURE PROSPECTS 
Most of the findings reported have not yet led 
to direct clinical applications. Indeed, only the 
synthetic ACTH peptide analogues have reached 
the clinical study stage. The reasons for the 
absence thus far of clinical applications of neu-
rotrophic factors are obvious: CNTF, BDNF, 
NT-3 and NT-4 have been cloned during the last 
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3 yr, and the physiological role played by these 
factors is far from being fully understood. In 
addition, problems in the production of high 
quantities of recombinant factors in active and 
pure form, a prerequisite for future clinical 
studies, have not yet been fully solved. CNTF is 
the only neurotrophic factor to date for which it 
seems that sufficient amounts of the recombinant 
human factor necessary for clinical studies might 
be available in the near future. 
Clinical studies with neurotrophic factors 
should be of particular value in cases where the 
degeneration of the spinal motoneurons is in 
total or in part due to the restricted availability of 
a neurotrophic factor : substitution of the missing 
factor should then prevent progression or even 
alleviate the symptoms of patients suffering from 
such diseases. However, nothing is yet known as 
to whether such cases of neurogenic muscular 
dystrophy which are caused by reduced expres-
sion of neurotrophic molecules exist. Therefore 
the identification of neurotrophic factors and 
other survival factors for spinal motoneurons is 
only the first step towards treatment of spinal 
muscular atrophy. The characterization of the 
molecular mechanisms leading to the disease 
state is a second prerequisite for rational thera-
peutic steps. The establishment of an organized 
nerve tissue bank might be an important step 
towards addressing such questions during the 
coming years. 
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